Concepedia

Caitlin Routhier

CR

Statistics

Publications

6

Citations

304

H-Index

6

Active since

2012

Affiliations

Mersana Therapeutics (United States)(Current)

Massachusetts General Hospital

Harvard University

Caitlin Routhier is an author at Mersana Therapeutics (United States) specializing in oncology, medicine, and pharmacy.

Publications per year

2012–2025

6

Publications

6

Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas

Caitlin Routhier, Mark C. Mochel, Kerry D. Lynch et al. · Human Pathology · 2013 · 117 citations

Medicine, Oncology, Pathology +17

Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses

Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James et al. · Nature Communications · 2024 · 72 citations · Full text

Life Sciences, Immunology, Oncology +17

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Dorin Toader, Shawn P. Fessler, Scott D. Collins et al. · Molecular Cancer Therapeutics · 2023 · 39 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17

XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells

Raghida A. Bukhalid, Jeremy R. Duvall, Kelly L. Lancaster et al. · Clinical Cancer Research · 2025 · 36 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas et al. · Cancer Research · 2022 · 24 citations

Pharmacy, Oncology, Pharmacology +17

1–5 of 6